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Abstract
Background: A better understanding of the natural history of osteogenesis imperfecta (OI) in adulthood should
improve health care for patients with this rare condition.
Methods: The Osteogenesis Imperfecta Foundation established the Adult Natural History Initiative (ANHI) in 2010 to
give voice to the health concerns of the adult OI community and to begin to address existing knowledge gaps for
this condition. Using a web-based platform, 959 adults with self-reported OI, representing a wide range of self-
reported disease severity, reported symptoms and health conditions, estimated the impact of these concerns on
present and future health-related quality of life (QoL) and completed a Patient-Reported Outcomes Measurement
Information System (PROMIS®) survey of health issues.
Results: Adults with OI report lower general physical health status (p < .0001), exhibit a higher prevalence of
auditory (58 % of sample versus 2–16 % of normalized population) and musculoskeletal (64 % of sample versus
1–3 % of normalized population) concerns than the general population, but report generally similar mental health
status. Musculoskeletal, auditory, pulmonary, endocrine, and gastrointestinal issues are particular future health-
related QoL concerns for these adults. Numerous other statistically significant differences exist among adults with
OI as well as between adults with OI and the referent PROMIS® population, but the clinical significance of these
differences is uncertain.
Conclusions: Adults with OI report lower general health status but are otherwise more similar to the general
population than might have been expected. While reassuring, further analysis of the extensive OI-ANHI databank
should help identify areas of unique clinical concern and for future research. The OI-ANHI survey experience
supports an internet-based strategy for successful patient-centered outcomes research in rare disease populations.
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“Progress can be made when patients and researchers
collaborate towards a common goal [1].”
Background
Osteogenesis imperfecta (OI) is a heterogeneous group
of inherited connective tissue diseases defined clinically
by excessive skeletal fragility and recurrent fracture [2].
With an estimated prevalence of 8 cases per 100,000
persons, perhaps 30,000 live with OI in the United States
[2]. The Sillence classification for OI, first described in
1979, includes four types (I-mild, II-neonatal lethal,
III-severe, progressively deforming, and IV moderately
severe), and is almost exclusively based on physician
perception of disease severity [3].
Most OI cases are caused by mutations in the type I col-
lagen genes and are the result of autosomal dominant in-
heritance. During the past several years, the spectrum of
OI has expanded to include rare, recessively inherited
forms resulting from abnormalities in the post-translational
modification of type I collagen, as well as abnormalities in
regulatory proteins involved in bone matrix homeostasis,
including those of the Wny-signaling pathway [4, 5].
These non-classical forms of OI can range from moderate
severity to neonatal lethality in presentation.
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While the cardinal clinical manifestation of OI is frac-
ture [2], deficiencies in collagen-rich tissues other than
bone can lead to abnormal dentition [6], joint laxity [7, 8],
hearing loss [9], ocular disease [10], pulmonary [2], and
vascular and valvular heart disease [11]. Disease severity
ranges from perinatal death to minimally symptomatic
forms that escape detection into adulthood [2]. Height-
ened diagnostic awareness and improved treatments, par-
ticularly in severe forms, has increased the number of
adults living with OI [12]. While adolescents and young
adults with OI may be medically sophisticated, their tran-
sition to a new adult health care provider and system of
care can be daunting. Adult health care providers and sys-
tems have a paucity of medical evidence to guide them
and likely little first-hand experience with this condition
[13]. Similarly, physically accessible, high quality, informed
health care may not be readily available to many [14] and
some adults with OI feel that the strong association of OI
with “brittle bones” diverts attention away from other im-
portant adult health care concerns.
Limited research exists regarding the health issues of
adults with OI [7, 8]. Although adults with OI report a
high level of life satisfaction, any conclusions drawn from
available reports are constrained by the small number of
subjects, the focus on milder forms of OI, and the absence
of disease specific quality of life (QoL) measures. Thus,
adults with OI, their families and their health care pro-
viders cannot formulate expectations of their future
health-related QoL, nor anticipate their long-term health
care needs. Moreover, despite the potential for mortality
and significant morbidity suffered by OI patients, all mea-
sures of OI outcomes have been developed by experts
without input from patients and rely on clinician-based
assessments rather than actual patient reports.
Directly engaging the OI community in patient-centered
outcomes (PCO) research could mitigate some of these
challenges [1, 15]. To address concerns raised by the adult
OI community and to begin closing the knowledge gap,
the Osteogenesis Imperfecta Foundation (OIF) assembled
a committee composed of adults with OI (including a
practicing physician), orthopedic and medical specialists
with extensive experience in the care of persons with OI,
OIF representatives, research scientists, and statisticians
and created the Osteogenesis Imperfecta Adult Natural
History Initiative (OI-ANHI) in 2010. The OI-ANHI
tested the feasibility of using web-based, PCO methods for
rare disease research by creating an on-line health survey
to (1) define health care concerns and perceptions of
adults with OI; (2) identify health-care related issues that
may have been previously missed or under-valued by
adults with OI and their medical providers; and (3) com-
pare QoL responses by adults with OI with those of
benchmark populations without OI. This paper reports
the initial results of the OI-ANHI survey.
Methods
Based on adult focus group meetings conducted by OI-
ANHI committee members at the 2010 bi-annual OIF
meeting for persons with OI and their families, a web-
based survey was designed and implemented to capture
the health status, concerns, needs, and priorities of adults
with OI. The complete OI Adult Natural History Initiative
survey is available as Additional file 1. The survey was pre-
sented in the following sequence: (1) collection of general
anthropomorphic, demographic, and medical information;
(2) an organ-system-based, medical “review of systems”
(ROS) followed by a 5-point Likert ranking to assess the
impact of each organ-system on current and expected fu-
ture QoL; (3) multiple instruments from the Patient-
Reported Outcomes Measurement Information System
(PROMIS®) to evaluate the level of health and functioning
for core physical, mental, and social health constructs that
are normed to the US general population [16].
Anthropometric data included height and weight.
Demographics included year of birth, gender, race/ethni-
city, education level, and current country of residence.
Medical information addressed medical diagnoses, test-
ing and interventions, and various lifestyle factors. Data
collected include OI Sillence Classification, additional
medical diagnoses, primary means of mobility, list of
health care providers, surgical health interventions, and
level of physical activity among other variables.
We queried severity of OI in three different ways: first,
respondents provided their understanding of their Sillence
type; secondly, they reported whether they perceived their
disease to be mild, moderate or severe; height provided an
objective measure that has been shown to correlate with
disease severity [17].
The second portion of the survey was a medical review
of systems (ROS), developed as a collaborative effort by
the group of authors, which included physicians, persons
with OI, and their advocates, yielding a comprehensive,
textbook-quality medical ROS and potentially identifying
previously underemphasized or unidentified health con-
cerns. (Additional file 1) We assessed respondents’ phys-
ical health within fifteen organ systems: neurologic,
urinary, musculoskeletal, auditory, cardiovascular, skin,
vision, dental, pulmonary, gastrointestinal, endocrine,
hematologic, oral, obstetric/gynecologic (females only),
and male sexual function (males only). We then used a
tri-part format to assess the impact of each system on
the respondent’s QoL. The first question asked whether
or not the respondent had any of the concerns listed
specific to the system (e.g. for the skin, rashes and pres-
sure sores; for the pulmonary system, shortness of
breath, pneumonia, etc.). The second and third ques-
tions for each organ system queried respondents via a 5-
point, Likert rating scale as to how much issues within
the relevant organ system currently impacted their QoL
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and how much they thought problems with each system
would impact their quality of life in the future.
The third and final portion of the survey used selected
PROMIS® item banks to evaluate general physical health,
pain, fatigue, physical function, sleep, depression, anxiety,
sexual satisfaction, and social function. Point values for
PROMIS® construct responses were calibrated to T-scores
generated from a representative U.S. population and re-
ported on a 100-unit scale where the mean is set at 50
units, with 10 units representing one standard deviation
(SD). This data transformation follows the guidelines set
forth in PROMIS® methodology [18]. Means and 95 %
confidence intervals for the OI population were calculated
based on individual T-scores for a given concept. The
minimum important difference (MID) in PROMIS® re-
sponses thought to be clinically relevant has been esti-
mated as 0.3–0.5 SD for fatigue, anxiety and depression;
0.4–0.6 SD for pain; and 0.2 for physical function [19, 20].
Participants accessed the survey through a web-based
portal and were recruited with two OIF postal mailings,
a notice posted on the OIF web-site, the OIF newsletter
Breakthrough, spoken and written notification at na-
tional and regional clinical and scientific meetings, social
networks (Facebook, Twitter, OI forums and chat-rooms),
and word of mouth. Children’s National Health System’s
Institutional Review Board exempted the survey from re-
view, as it was anonymous. Prior to participation, respon-
dents read the study’s purpose, gained study contact
information, learned of the right to withdraw, and then
chose either to participate or not participate. The survey
instrument was available from 10/01/2011 to 12/31/2011
and designed so that respondents could complete the sur-
vey progressively. Those without computer access or facil-
ity were offered a paper version, and a data entry specialist
masked to subject identity uploaded completed results.
Paper surveys were accepted until midnight 01/02/2012.
The survey required at least one hour, but more than
likely, two hours for completion. Only respondents who
answered at least one question in the final PROMIS® item
set (Sleep Disturbance) were considered to have com-
pleted the entire OI-ANHI survey.
Body Mass Index (BMI) was calculated as kg/m2 and
classified according to the World Health Organization
(WHO) weight classification criteria [21]. Height Z-scores
were calculated from the National Health and Nutrition
Examination Survey (NHANES III) dataset [22]. Height
Z-scores indicate the number of SD a reported height var-
ies from a US adult, gender matched mean. To compare
the PROMIS® scores of the generalized population with
those of our sample, we segregated PROMIS® T-scores by
both OI self-reported severity grouping (mild, moderate,
severe) and by quartile of height Z-score. For continuous
variables, a t-test was used to calculate the p-value; for
dichotomous variables, a chi-square test was used. For
variables reported on a Likert scale, a generalized linear
model was utilized (SAS proc glm). Generalized linear
models were also used to compare differences among OI
groups. All analyses were performed using SAS version
9.2 (SAS institute, Cary NC).
Results
Of 1,183 individuals who initiated the survey, 959 (82 %)
successfully completed it, constituting the study sample.
Demographically, respondents were female (71 %), middle
aged (mean 45.1 ± 15.0 years, range 18–89 years),
Caucasian (91 %) and lived in North America (89 %).
Figure 1 is a graphical depiction of age distribution. Age
did not vary on the basis of self-reported severity grouping
(Fig. 2). Highest educational achievement exceeded sec-
ondary school for 82 %. In regard to anthropometric data,
average height was 57.3 ± 9.2 inches, weight 135.9 ± 44.6
pounds, and BMI 29.4 ± 9.3.
In response to the OI-specific medical questions, the
majority walked unaided (61 %), but 16 % required a
cane, crutches or walker, and nearly one-quarter re-
ported regular wheelchair use. The majority had received
their OI diagnosis from a doctor (59 %). Respondents
considered their OI to be mild (56 %), moderate (35 %)
or severe (9 %) and reported Sillence classifications of
Type I (39 %), Type III (13 %), and Type IV (12 %). Fewer
than 5 % described other Sillence types and 31 % reported
their type to be unknown. Table 1 shows the relationship
between self-reported disease severity and self-reported
Sillence type. As self-reported disease severity worsened,
height Z-score decreased (β = -0.13, p < 0.0001, Fig. 3).
A large proportion of participants (65 %) consumed vi-
tamins or dietary supplements, followed by pain (40 %)
and blood pressure medications (32 %). Medical pro-
viders reported to be actively involved in respondents’
medical care included a “general medical doctor” (92 %),
orthopedist (49 %), gynecologist (40 % of women), and
endocrinologist (21 %). Cardiologists, dermatologists
and gastroenterologists were involved in 10 % of
Fig. 1 Histogram displaying age distribution for all respondents
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respondents’ care, but few other medical specialists had
ever been engaged. Other providers were dentists (68 %)
and ophthalmologists (30 %). Both overall and when sepa-
rated by self-reported severity grouping, respondents saw
a median number of 4 different care providers. The overall
range was 0 to 14 (Fig. 4). Number of health care pro-
viders seen did not vary on the basis of self-reported OI
severity grouping. Notably, just over half of participants
reported no health interventions (52 %), while 35 % had
received rodding surgery. Other than the two aforemen-
tioned responses, respondents indicated a scant number
of other health interventions. Many of the respondents
had received medical testing in the prior year with 86 %
reporting a blood pressure reading, 71 % a vision
exam, 66 % a blood test for cholesterol, and 34 % a
DXA scan. Respondents reported very few cancer
diagnoses, with the majority reporting none (90 %)
followed by skin cancer (4 %).
Respondents acknowledged few general health con-
cerns, with “none of these” (52 %) as the most endorsed
response followed by changes in sleep patterns (27 %)
and mood swings (20 %). Almost half of respondents (49
%) engaged in walking as a regular physical activity al-
though approximately one-third (34 %) reported that
they do not exercise regularly. There was a significant
relationship between engagement in physical activity and
severity grouping (Fig. 5). The most popular exercise
Fig. 2 Histogram depicting age in five-year groups by self-reported severity grouping. Three categories of severity are reported: mild, moderate,
and severe
Table 1 Relationship between self-reported Sillence type and
self-reported disease severity in adults with OI
Self-reported disease severity
n (% of OI type)
OI type n (%) Mild Moderate Severe
I 369 (39) 308 (83) 59 (16) 2 (<1)
II 26 (3) 12 (46) 8 (31) 6 (23)
III 125 (13) 7 (1) 67 (20) 51(57)
IV 110 (12) 45 (41) 55 (50) 10 (9)
V 14 (1) 2 (14) 11 (79) 1 (7)
VI 2 (<1) – 1 (50) 1 (50)
Bruck’s syndrome 3 (<1) – 3 (100) –
Unknown 295 (31) 154 (52) 123 (42) 18 (6)
Total 944 (100) 528 (56) 327 (35) 89 (9)
Missing n = 15
Fig. 3 Box plot representing self-reported OI severity and NHANES-III
Z-score for height. The diamonds represent the mean and the
horizontal lines within the box the median height Z-score. The upper
and lower bounds of the box represents the 75th and 25th percentile
for height Z-score respectively. The whiskers represent the minima
and maxima height Z-score values and open circles represent
outliers
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venue was the home (51 %), and respondents oftentimes
developed their own exercise programs (40 %).
Only 2 % of respondents reported having no medical
provider and 4 % considered urgent care or emergency
room providers to be their primary source of health
care. Ninety-one percent of respondents had health care
insurance. Many adults with OI turn to their medical
providers for health-related information (53 %); however,
more rely on the Internet (63 %) and the OIF (71 %) for
that information. Indeed, only 32 % indicated “quite a
bit” or “very much” confidence in their primary care
provider’s medical management of their OI. Approxi-
mately one-third of respondents reported no regular
dental care.
Table 2 summarizes prevalence for various self-reported
conditions and symptoms, segregated by self-reported dis-
ease severity, compared to similar results reported in the
NHIS 2012 [23] and other benchmark datasets [24–38].
Musculoskeletal problems (particularly fractures), hearing
loss, heartburn, and astigmatism differ most between OI-
affected adults and the general population. Reports of dry
skin, numbness, sleep apnea, hemorrhoids and shortness
of breath appear to be more prevalent in adults with OI.
Only fracture, hearing loss and to some extent heartburn
and constipation relate to OI severity. In regard to obstet-
ric/gynecological health, an unexpected finding was that
one-third of adult women with severe OI reported a prior
pregnancy, with only 6 % reporting miscarriage and none
reporting stillbirths. Among the women in our sample 55
years of age and younger, those reporting severe OI expe-
rienced significantly less (p < .05) catamenial bleeding than
those with mild or moderate OI.
The organ systems most often reported to affect current
QoL are urinary tract (97 %), musculoskeletal (95 %), vi-
sion (82 %), auditory (75 %), dental (74 %), skin (68 %),
gastrointestinal (65 %), and neurological (64 %). Using a
Likert scale, Fig. 6 shows the impact of specific organ sys-
tem concerns on current and anticipated future QoL for
all respondents (Fig. 6 left) and for those already experien-
cing problems within that organ system (Fig. 6 right). Dis-
proportionate concern was reported for future pulmonary,
cardiologic and vision issues by all respondents, and for
endocrine, pulmonary and cardiovascular issues in those
respondents already experiencing issues in these domains.
Figure 7 shows the mean PROMIS® T-scores of se-
lected items by self-reported OI severity compared with
the PROMIS® population norm. General physical health
status was significantly lower than that of the general
population and the magnitude of difference (0.4–1.0 SD)
exceeded the MID established for several PROMIS® do-
mains [19, 20]. General physical health among the OI
cohort was lower in those reporting greatest disease
Fig. 4 Histogram displaying number of healthcare providers seen for
all respondents
Fig. 5 Histogram depicting engagement in or disengagement from exercise by self-reported severity grouping. A response of “1” correlates with
“yes” for exercise while “0” represents a response of “no.” Three categories of severity are reported: mild, moderate, and severe
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severity but the magnitude of this difference was small.
Results also revealed small but statistically significant
differences between adults with OI and the normative
population for a number of the PROMIS® scales; adults
with OI reported greater levels of anxiety (p < .0001) and
depression (p < .0001), as well as lower levels of general
mental health (p < .0002). However, the differences in
means between adults with OI and the normative popu-
lation for these three scales did not qualify for clinical
relevance according to the established MIDs [19, 20].
Segregation of PROMIS® T-scores by quartile of height
Z-score (Fig. 8) demonstrates results similar to Fig. 7
and shows that decreased height does not consistently
correlate with less desirable PROMIS® scores within our
adult OI sample for certain scales, including access to
help and satisfaction with social roles.
Remarkably, adults with OI report lower pain intensity
than the general PROMIS® population. While adults with
OI indicate that pain interferes with their functional
state significantly more than it does for the general
Table 2 Prevalence of self-reported conditions and symptoms by adults with OI shown by self-reported disease severity compared
with prevalence reported by both genders in NHIS 2012 or, where specified, in other adult benchmark databases
Condition Prevalence of reported conditions and symptoms (%)
Mild OI Moderate OI Severe OI All NHIS 2012 [23]
(n = 535) (n = 329) (n = 92) (n = 959)
Astigmatism 33 37 30 34 3.6 [24]
Blood vessel problem (rupture, aneurysm) 5 6 10 6 1–12 [25]
Bruising 47 41 15 42 18 (12–55)
Cancer 11 9 4 10 5–8 [26]
Cataracts 8 9 11 8 8.6 [25]
Constipation 23 29 34 26 12–19 [27, 28]
Coronary artery disease 6 11 8 4, 7 5–17 (<65 yr)
20 12 0 10, 10 30 (>65 yr) [25]
Heart attack 6 9 7 7 2.9 (>20 yr) [25]
Cough 11 19 30 16 9–33 [29]
Diabetes mellitus 11 11 8 11 8–10 [23]
Dry skin 35 30 28 32 14–19 (<65 yr)
49 62 0 52 56 (>65 yr) [30]
Fractures 59 72 66 64 1–3 [31]
Fragile teeth 29 46 57 38 10–19 [32]
Glaucoma 8 7 2 7 2 [24]
Hearing loss 59 57 58 58 2–16 [23]
Heart valve problem 6 9 4 7 2–4 [25]
Heartburn 30 40 30 33 3–7 [33]
Hemorrhoids 17 18 11 17 4 [28]
High cholesterol 29 27 12 26 8–27 [23, 25]
Hypertension 32 42 34 35 21–36 [34]
Kidney/bladder stones 8 14 4 9 8.8 [35]
Near sightedness 50 49 39 49 33–40 [24]
Numbness 18 22 25 20 0.1–8 [36]
Obesity (BMI > 30 kg/m2) 29 42 50 35 28–35 [23]
Shortness of breath 20 31 47 26 10–18 (<65 yr)
28 31 60 31 30 + (>65 yr) [37]
Sleep apnea 9 17 32 14 <6 [38]
Stroke 3 6 8 4 3 [25]
Wheezing/asthma 12 14 27 14 8–13 [37]
NHIS 2012: “Any hearing trouble without use of hearing aid or listening device”
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PROMIS® population, this difference appears to be less
than the MID and results did not differ by self-reported
disease severity.
Only those adults with severe OI appeared to report
notably (-0.56 SD) lower satisfaction with sexual activity.
Statistically significant differences in T-scores for re-
sponses to “sleep disturbance”, “satisfaction with social
roles” “fatigue”, “access to help”, and “ability to partici-
pate in social activities” were found between the OI co-
hort and the general PROMIS® population but these
differences appear to be less than a MID.
Discussion
Delineating and meeting the health needs of adult survi-
vors of childhood-onset conditions is a growing quality-
of-care issue. Based on estimates of those living with OI in
the US ranging from 25,000 [39] to 50,000 [40], approxi-
mately 3 % of the total US OI population completed the
OI ANHI survey. This number is especially impressive
given the fact that adults with OI are a rare, geographically
dispersed population and that we recruited respondents in
an incentive-free manner. In doing so, we have demon-
strated how persons with rare (and not so rare) conditions
can collectively address some of their important health re-
lated concerns as a virtual community.
Demographics and medical/lifestyle information
BMI exceeded the WHO diagnostic threshold for obesity
(30 kg/m2) in 36 % of respondents and an additional 31
% were overweight. While this prevalence is similar to
the general adult US population, it is unclear that this
finding conveys the same health risk for an individual
whose height is 5 or more SDs below average. Hyperten-
sion has been reported to be more prevalent in adults
with OI but this was not the case in our population.
Unexpectedly, adults with self-reported severe OI re-
ported substantially less catamenial bleeding than those
reporting mild or moderate disease. Heightened vigi-
lance for cutaneous trauma or the protective effect of a
wheelchair might explain the former but could not ac-
count for the latter. While vague, the large number of
respondents reporting numbness suggests the need for
further inquiry as the incidence of basilar invagination, a
potential explanation for numbness, is much higher in
persons with OI than the general population.
Neither age nor number of health care providers seen
varied by self-reported OI severity grouping. The finding
regarding age was surprising as we anticipated that those
individuals with more severe forms of OI would be
younger because of the higher number of medical and
musculoskeletal problems that can accompany more se-
vere disease. While those with the milder types of OI,
such as types I and IV, can anticipate a normal lifespan,
prior research has found a reduced lifespan for those
with type III OI [12, 41].
The findings that age does not vary on the basis of the
subjective self-reported grouping and that height is an
inconsistent predictor of quality of life suggest the same
outcome: there are important aspects of OI severity and
functioning not captured by some of the markers relied
upon in the past, including age and height. These incon-
sistencies underscore the need to validate the PRO-
MIS® instruments for use in OI and to develop disease-
specific QoL measures in order to better assess function-
ing in adults with OI. Satisfaction with sexual activity
was the only construct that revealed statistically signifi-
cant differences between groups.
We determined significant differences in exercise
engagement based on perceived disease severity. This
finding deserves further inquiry. Given that this was a
Fig. 6 The impact of specific organ system concerns on current and anticipated future QoL for all respondents (left) and for those already
experiencing problems within that organ system (right) described using a 5-point Likert scale ranking of organ-system-based concerns from least
(1) to greatest (5) impact on current and anticipated future quality of life
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self-reported disease severity rating rather than Sillence
classification, do adults who report more severe OI in-
deed abstain from physical activity because of the sever-
ity of their condition or are there individuals with more
mild forms of OI reporting greater OI severity because
their condition has potentially also worsened from exer-
cise abstinence? Previous research among adults with OI
determined a correlation between decreased physical
function and ability to participate in the physical actions
of climbing stairs and going for walks [8]. Similarly, a
study among pediatric patients with OI found that walk-
ing ability suffered with greater OI disease severity [42].
Such research suggests that physical activity participa-
tion is not only a challenge in OI, but also becomes less
likely with augmented OI severity.
However, physical activity, especially physiotherapy in-
volving muscle strengthening, is an important aspect of
OI management [8] and physical activity has been shown
to improve functioning in pediatric populations with
mild to moderate OI [43]. Unfortunately there are no
studies to guide persons with severe OI. In light of our
finding that adults with self-reported, severe OI show
greater disengagement from exercise, future studies
should examine this association and its determinants. In
turn, longitudinal research should examine the poten-
tially protective effect of exercise by all types of OI dis-
ease severity.
Organ-specific quality of life concerns
Adult OI respondents indicate that musculoskeletal and
auditory issues have a greater impact on current and an-
ticipated future QoL than other organ system concerns,
and express even greater concern about the future im-
pact of endocrine and pulmonary issues on QoL. Re-
spiratory failure is a leading cause of death in severe OI
[12, 41]. The lungs are often greatly affected in OI, with
challenges such as pulmonary restrictive disease due to
chest wall or pulmonary collagen abnormality, airway
obstruction, pulmonary hypertension, and sleep apnea
[44]. Care recommendations have been developed by
Sandhaus, which include intensive, longitudinal follow-
up of pulmonary function in patients with OI [44]. This
is particularly important given the high rates of seden-
tarism and elevated BMI reported [12, 45]. Therefore,
the low rate of reported pulmonary consultation could
be an opportunity for improving care and health status.
Up to 50 % of adults with OI have dentogenesis imper-
fecta [6] yet approximately one-third of our respondents
reported no regular dental care, and 74 % expressed
current QoL concerns regarding their dental health. An
important future research direction should include a more
in-depth analysis of dental care in OI to establish whether
adults with OI have difficulty gaining access to dental care
or whether there is another explanation for this shortfall.
Fig. 7 Mean PROMIS® T-scores with 95% confidence limits by self-
reported OI severity. Symbols represent self-reported OI severity
(▲ = mild, ■ = moderate, ● = severe). The mean T-scores of the
PROMIS® referent population are indicated by the solid vertical
reference line placed at “50”. Therefore, symbols to the right of the
reference line are higher than the PROMIS® population mean (i.e.
more of that construct than the PROMIS® population) and symbols to
the left of the reference line are lower than the PROMIS® population
mean (i.e. less of that construct than the PROMIS® population). p-values
are for the comparisons of T-scores within disease severity strata
amongst the entire OI cohort (left column, “OI severity”) and between
the entire OI cohort and the general PROMIS® population (right
column, “Population”)
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Multiple insights into improving research and care
were gleaned from the ROS. Results from the QoL por-
tion of the medical ROS revealed that adults with OI
have future-related QoL concerns with organ systems
identified as troublesome, particularly the musculoskel-
etal, auditory, and pulmonary subsystems. In addition,
respondents expressed future-related, QoL concerns with
the endocrine and gastrointestinal organ systems, subsys-
tems that have not been heavily studied in the existing OI
literature. For better incorporation of patients’ concerns
into care and integration of what doctors know to be im-
portant with what matters to patients, exploration of the
Fig. 8 Mean PROMIS® T-scores with 95% confidence limits by quartile of NHANES-III Z-score for height. Symbols represent self-reported OI severity
(▲ = mild, ■ = moderate, ● = severe). The mean T-scores of the PROMIS® referent population are indicated by the solid vertical reference line
placed at “50”. Therefore, symbols to the right of the reference line are higher than the PROMIS® population mean (i.e. more of that construct than
the PROMIS® population) and symbols to the left of the reference line are lower than the PROMIS® population mean (i.e. less of that construct than the
PROMIS® population). p-values are for the comparisons of T-scores within disease severity strata amongst the entire OI cohort (left column, “OI severity”)
and between the entire OI cohort and the general PROMIS® population (right column, “Population”)
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endocrine and gastrointestinal subsystems represents an
important future research direction.
Patient-centered/patient-reported outcomes: PROMIS®
As according to PROMIS®, adults with OI report lower
general physical health status than the general popula-
tion. General physical health status among respondents
reporting the greatest disease severity was lower, but the
clinical significance of this finding is uncertain. Numer-
ous statistically significant differences exist among adults
with OI of varying severity as well as between adults
with OI and the general population, but the clinical sig-
nificance of these differences is uncertain. Indeed, the
PROMIS® instruments suggest that, overall, the OI com-
munity does not differ greatly from the general popula-
tion. Moreover, the results of the OI-ANHI survey
support previous findings that adults with OI report a
high level of life satisfaction in spite of a significant dis-
ease burden which, in our collective experience, the au-
thors would characterize as resilience [7, 8, 46].
We and others have shown significant correlations be-
tween disease severity and height Z-score [17], but when
PROMIS® T-scores are segregated by quartile of height
Z-score, our results suggest that these measures may
convey slightly different QoL information in this popula-
tion. Clinicians encounter adults with ostensibly mild OI
who consider their condition to be severe when their
only objective manifestation of OI is adult-onset deaf-
ness. Perhaps “severity” should also be viewed from the
patient’s perspective and not only by height Z-score or
Sillence type. Whether nuances in QoL information con-
veyed by these different measures are important is
unknown but, if so, they could be relevant to the devel-
opment of a disease-specific QoL instrument for OI.
The PROMIS® scales are validated and scaled for a
healthy, adult population, which represents a challenge
in their application to a chronic, rare disease group. Al-
though our results suggest that adults with OI exhibit
similarities with the normative population, it is possible
that the scales are not capturing some differences within
our sample. The validation of PROMIS® instruments for
persons with OI will be an important future study focus
so that researchers can better understand QoL in OI and
move towards the application of PROs both in clinical
settings and comparative effectiveness research [47].
Limitations
Most likely, our recruitment and web-based strategies
resulted in a self-selection/enrollment bias. We were
likely unable to capture the responses of non-Internet
users in this study. Nonetheless, our study represents
the first effort to query a large sample of adults with OI
regarding their disease burden and QoL. Although our
study relied heavily on an Internet rather than a paper
format, several studies have quantified the reliability of
Internet research studies by comparing them to identical
studies conducted with non-internet formats and have
found them to be equally as reliable [48, 49]. Internet
methods have been shown to be as reliable as paper for-
mats when measuring patient-reported health outcomes
for those suffering from chronic health conditions [50].
Our results may be limited by the restricted demo-
graphic heterogeneity of our sample. Male gender, lower
educational achievement status, and non-Caucasian race
were all under-represented. Previous research has shown
that women generally rely on the Internet for health and
medical information more than men [51]. In addition, as
of 2015, those with college education are more likely
than those who do not have high school diplomas to use
the Internet and the minority groups of African American
and Hispanic ancestry are less likely to be Internet users
than Caucasians [52]. These noted differences in Internet
usage may partially explain why our sample proved to be
predominantly female, well educated, and Caucasian.
However, previous studies examining OI have also noted a
higher proportion of female [7, 8, 38], more highly edu-
cated [45], Caucasian [38] respondents, (the majority of
whom describe themselves as having type I OI) [38].
Multiple other studies have also reported a middle-
aged mean [7, 8, 45]. Thus, our study accessed those
members of the OI community most often reported in
other research studies. One of our future goals is to
reach the populations under-represented in this study,
namely men, minorities, and those with a lower level
of education.
Another limitation of this study was the challenge of
defining disease severity. Even before Sillence developed
the current OI classification in 1979, efforts to stratify
disease severity had been ongoing and continue to be a
challenge because of the expanding clinical and genetic
heterogeneity found by researchers. At present, 17 differ-
ent genetic causes of OI have been identified [53] and it
is anticipated that more will be elucidated. Therefore,
the effort to define disease severity is a continuous
struggle in OI research. Furthermore, misclassification of
OI type was possible due to the self-report nature of our
research. Indeed, 31 % of respondents were unaware of
their Sillence type, and twelve respondents characterized
their OI as both Type II and mild, which, until recently,
was considered lethal.
In this study, however, we attempted to focus less on
Sillence classification, as our goal was greater inclusion
of the patient’s perspective and his or her own assess-
ment of functioning and disease burden. Indeed, it has
been documented that physicians and patients some-
times disagree on disease severity in chronic diseases.
Lack of concordance between physician and patient rat-
ings of disease severity in rheumatoid arthritis is an apt
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example [54, 55]. Therein, we developed the severity
measure for this study in a self-report format. Yet, ob-
jective measures of OI severity were not absent from our
work. Rather than rely fully on Sillence classification, we
included height as an objective marker of disease severity
and then examined its relationship with both self-reported
disease severity as well as the PROMIS® instruments.
Chief among the study’s strengths is the very large
number of respondents and the PCO perspective of this
inquiry. The success of this survey in reaching a large
number of adults with OI has encouraged our research
team to explore new strategies to engage the groups
that were underrepresented in the survey, namely
men, persons of limited educational achievement, and
non-Caucasians.
Conclusion
The OI-ANHI survey engaged an adult OI community
to identify issues of specific health-related QoL concern
and to focus future research efforts designed to improve
quality of care. Our results revealed that while adults
with OI exhibit similarities with the normative popula-
tion, there are important differences, including a higher
prevalence of musculoskeletal and auditory problems
and specific QoL concerns regarding the musculoskel-
etal, auditory, pulmonary, and endocrine systems. Our
future research will focus on expanding the range of
health care topics pursued in OI research and on incorp-
orating patients’ QoL concerns into effectiveness evalua-
tions of diagnostic and treatment strategies. Finally, we
will strive to develop methodologies that allow us to be
more inclusive and engage the broader OI community in
our future research studies.
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